RecruitingNCT00903110
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Studying Growth delay due to insulin-like growth factor type 1 deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Esteve Pharmaceuticals, S.A.
- Principal Investigator
- Global Program Clinical LeadEsteve
- Intervention
- Increlex®(drug)
- Enrollment
- 500 enrolled
- Eligibility
- 2-18 years · All sexes
- Timeline
- 2008 – 2027
Study locations (30)
- Children's Hospital of Orange County, Orange, California, United States
- University of Miami Leonard M Miller, Miami, Florida, United States
- University Of Miami Leonard M. Miller, Miami, Florida, United States
- D&H National Research Centers, Miami, Florida, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- UT Southwestern Medical Center, Dallas, Texas, United States
- Children's Health Specialty Center West Plano, Plano, Texas, United States
- Salzkammergut-Klinik Vöcklabruck, Vöcklabruck, Austria
- Hôpital Amiens-Picardie, Amiens, France
- Centre Hospitalier de Blois, Blois, France
- Hôpital Jean Verdier, Bondy, France
- Hôpital Femme Mère-Enfant, Bron, France
- Hôpital Estaing, Clermont-Ferrand, France
- Hôpital Timone Enfants, Marseille, France
- Hôpital Arnaud de Villeneuve, Montpellier, France
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00903110 on ClinicalTrials.gov